Composition
Citicoline sodium salt 0.2 g (g), sodium hyaluronate 0.02 g (g), sodium phosphate monohydrate, sodium dihydrogen phosphate dodecahydrate, sodium chloride, benzalkonium chloride, water for injections.
General characteristics
Mechanism of action:
Citicoline is a natural, physiological and main precursor in the synthesis of phospholipids of neuronal membranes. It provides structural restoration of the integrity of damaged nerve cell membranes, is a growth factor for optic nerve fibers in degenerative ophthalmological pathologies, such as glaucoma, glaucomatous optic neuropathy, ischemia of the optic nerve disc, as well as changes in the fundus associated with diabetes, hypertension (angiopathy, angiosclerosis, retinopathy). Due to the temporary and reversible relaxation of the corneal epithelial barrier and a low concentration (0.01%) of benzalkonium chloride - a penetration enhancer that stimulates the increase in intercellular gaps in the cornea, citicoline penetrates the anterior chamber of the eye and, by diffusion, through the vitreous body and uveo-scleral space reaches the retina and optic disc.
Hyaluronic acid is a natural high-molecular biopolymer, a non-sulfonated glycosaminoglycan, which is part of the connective, epithelial and nervous tissues in the human body. It is one of the main components of the extracellular matrix, which is contained in many biological fluids (saliva, synovial fluid, vitreous humor, etc.). Hyaluronic acid plays an important role in tissue hydrodynamics, as well as a significant participation in cell proliferation and migration, has proangiogenic properties, mucoadhesive and viscoelastic effects, which improves the stability of the tear film and keeps the ocular surface lubricated, moisturized and protected, creates a favorable microenvironment for the processes of re-epithelialization, restoration of the ocular surface in cases of corneal and conjunctival damage.
Hyaluronic acid helps retain the active ingredients of the drug on the surface of the eye (tear film) and prolongs the contact time of the citicoline molecule with the structures of the eye. It also acts as a conductor and promotes the migration of citicoline into the anterior chamber of the eye and the vitreous humor.
Indications for use
OMC1, due to its neurotransmitter, anti-degenerative, antioxidant, anti-anginal, metabolic effects and improvement of microcirculation, is recommended for:
- Glaucoma and glaucomatous optic neuropathy
- Diabetic retinopathy
- Ischemic optic neuropathy
- Macular dystrophies
- Degenerative corneal diseases
- Changes in the fundus of the eye associated with hypertension: angiopathy, angiosclerosis, retinopathy, etc.
- Keratitis
- Changes in the fundus of the eye associated with refractive errors: high-grade myopia, high-grade hyperopia, etc.
- Amblyopia
- Before and after keratorefractive surgeries: photorefractive keratotomy, LASIK, etc.
- Surgical interventions on the anterior segment of the eye.
Method of application
1 drop 2-3 times a day or as directed by a doctor.
The recommended course of treatment is 2 months three times a year, or 4 months twice a year (depending on the stage of the disease).
Side effects
Temporary blurred vision may occur after instillation. It is recommended to wait a few seconds before engaging in any activity that requires clear vision. In case of any adverse reaction, discontinue use of the solution and consult a doctor.
Contraindication
Individual hypersensitivity to the components of the drug.
Reservation
The solution is sterile until the vial is opened.
To prevent contamination of the solution, close the bottle tightly after use and do not touch the tip of the dispenser to the eye or other objects.
Do not use the solution if the vial is damaged.
After instillation, it is necessary to wait 10-15 minutes before using other local ophthalmic agents.
For external use in ophthalmology only.
Release form
Eye drops, solution.
Storage conditions
Store at a temperature not exceeding 25 °C out of the reach of children.
Expiration date
3 years. Do not use 30 days after opening the bottle and after the expiration date.
Producer
Omicron Italy S.R.L., Viale Bruno Buozzi, 5, 00197, Rome, Italy (Omikron Italia Srl, Via le Bruno Buozzi, 5, 00197, Rome, Italy.
Place of production:
FORMYGEYA S.P.A., Via G.B. Oliva 6, 56121, Pisa, Italy (FARMIGEA SpA, Via GB)
Representative
LLC "S.A.F.PHARMA", Sobornosti Ave., 7A, office 514, Kyiv, 02160, Ukraine.
